Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)

NCT00971126 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
3
Enrollment
OTHER
Sponsor class

Stopped Two patients in the first dose level be counted as reaching DLT. DSMB recommend terminated early this trial.

Conditions

Interventions

Sponsor

National Health Research Institutes, Taiwan

Collaborators